0000000001318661

AUTHOR

Angela Di Martino

showing 5 related works from this author

Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study

2022

To date there has been limited head-to-head evaluation of immune responses to different types of COVID-19 vaccines. A real-world population-based longitudinal study was designed with the aim to define the magnitude and duration of immunity induced by each of four different COVID-19 vaccines available in Italy at the time of this study. Overall, 2497 individuals were enrolled at time of their first vaccination (T0). Vaccine-specific antibody responses induced over time by Comirnaty, Spikevax, Vaxzevria, Janssen Ad26.COV2.S and heterologous vaccination were compared up to six months after immunization. On a subset of Comirnaty vaccinees, serology data were correlated with the ability to neutr…

COVID-19 VaccinesAd26COVS1vaccines.SARS-CoV-2ImmunologyCOVID-19serologyViral VaccinesvaccinesHumansB-cell memory; COVID-19; cell-mediated immunity; serology; vaccinescell-mediated immunityImmunology and AllergyB-CELL MEMORY COVID-19 CELL-MEDIATED IMMUNITY SEROLOGY VACCINESB-cell memoryLongitudinal StudiesB-cell memory; COVID-19; cell-mediated immunity; serology; vaccines; Humans; Aged; COVID-19 Vaccines; Longitudinal Studies; Ad26COVS1; SARS-CoV-2; COVID-19; Viral VaccinesAgedFrontiers in Immunology
researchProduct

First detection of SARS-CoV-2 A.23.1 sub-lineage in migrants arriving to Italy via the Mediterranean Sea and public health implications

2021

COVID-19 Mediterranean sea Migrants Molecular surveillance NGS Phylogeny analysis Public health SARS-CoV-2 Vaccination programs2019-20 coronavirus outbreakmedicine.medical_specialtyLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccination programsMigrantsArticlePhylogeny analysisMediterranean seamedicineHumansPhylogenyTransients and MigrantsPublic healthSARS-CoV-2Public healthPublic Health Environmental and Occupational HealthCOVID-19VirologyInfectious DiseasesGeographyItalyMolecular surveillanceNGSMediterranean seaTravel Medicine and Infectious Disease
researchProduct

Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022

2022

Background The SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021. Aim To comprehensively describe Omicron spread in Italy in the 2 subsequent months and its impact on the overall SARS-CoV-2 circulation at population level. Methods We analyse data from four genomic surveys conducted across the country between December 2021 and January 2022. Combining genomic sequencing results with epidemiological records collated by the National Integrated Surveillance System, the Omicron reproductive number and exponential growth rate are estimated, as well as SARS-CoV-2 transmissibility. Results Omicron became dominant in Italy less than 1 month after its first detection,…

Base SequenceSARS-CoV-2EpidemiologyCOVID–19 SARS–COV–2 DOUBLING TIME GENOMIC SURVEY OMICRON PREVALENCEprevalenceVaccinationPublic Health Environmental and Occupational HealthCOVID-19doubling timeomicronSettore MED/42 - Igiene Generale E Applicatagenomic surveyVirologySARS–CoV–2COVID–19HumansEurosurveillance
researchProduct

MOESM2 of Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004–2017

2019

Additional file 2: Figure S1. Violin plot comparing the median values (white dots), interquartile range (thick blue bar in the center) and distributions of age between influenza B/Victoria- and B/Yamagata-lineage cases.

researchProduct

MOESM1 of Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004–2017

2019

Additional file 1: Table S1. GISAID accession numbers (AN) for hemagglutinin (HA) of influenza B viruses generated in this study (*) and used for the phylogenetic analysis, along with other Italian sequences retrieved from GISAID or NCBI database and reference and WHO vaccine strains (in bold).

researchProduct